Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 365

1.

Price comparison of high-cost originator medicines in European countries.

Vogler S, Zimmermann N, Babar ZU.

Expert Rev Pharmacoecon Outcomes Res. 2017 Apr;17(2):221-230. doi: 10.1080/14737167.2016.1223543. Epub 2016 Oct 11.

PMID:
27658050
2.

Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study.

Vogler S, Vitry A, Babar ZU.

Lancet Oncol. 2016 Jan;17(1):39-47. doi: 10.1016/S1470-2045(15)00449-0. Epub 2015 Dec 4.

PMID:
26670089
3.

Analysis of Medicine Prices in New Zealand and 16 European Countries.

Vogler S, Kilpatrick K, Babar ZU.

Value Health. 2015 Jun;18(4):484-92. doi: 10.1016/j.jval.2015.01.003. Epub 2015 Apr 4.

4.

[Risk sharing methods in middle income countries].

Inotai A, Kaló Z.

Acta Pharm Hung. 2012;82(1):43-52. Review. Hungarian.

PMID:
22570986
5.

Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries.

Leopold C, Mantel-Teeuwisse AK, Vogler S, de Joncheere K, Laing RO, Leufkens HG.

Health Policy. 2013 Oct;112(3):209-16. doi: 10.1016/j.healthpol.2013.08.012. Epub 2013 Sep 8.

PMID:
24060335
6.

Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.

Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, Hill S.

PLoS Med. 2016 May 31;13(5):e1002032. doi: 10.1371/journal.pmed.1002032. eCollection 2016 May.

7.

Differential pricing of new pharmaceuticals in lower income European countries.

Kaló Z, Annemans L, Garrison LP.

Expert Rev Pharmacoecon Outcomes Res. 2013 Dec;13(6):735-41. doi: 10.1586/14737167.2013.847367. Review.

PMID:
24219049
8.

Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.

Stargardt T, Schreyögg J.

Appl Health Econ Health Policy. 2006;5(4):235-47.

PMID:
17249840
9.

Impact of external price referencing on medicine prices - a price comparison among 14 European countries.

Leopold C, Mantel-Teeuwisse AK, Seyfang L, Vogler S, de Joncheere K, Laing RO, Leufkens H.

South Med Rev. 2012 Dec;5(2):34-41. Epub 2012 Dec 27.

10.

The economics of parallel trade.

Danzon PM.

Pharmacoeconomics. 1998 Mar;13(3):293-304. Review.

PMID:
10178655
11.

Prices and distribution margins of in-patent drugs in pharmacy: a comparison in seven European countries.

Garattini L, Motterlini N, Cornago D.

Health Policy. 2008 Mar;85(3):305-13. Epub 2007 Oct 10.

PMID:
17928092
12.

Measuring access to medicines: a survey of prices, availability and affordability in Shaanxi province of China.

Jiang M, Yang S, Yan K, Liu J, Zhao J, Fang Y.

PLoS One. 2013 Aug 1;8(8):e70836. doi: 10.1371/journal.pone.0070836. Print 2013.

13.

Implications of external price referencing of pharmaceuticals in Middle East countries.

Kaló Z, Alabbadi I, Al Ahdab OG, Alowayesh M, Elmahdawy M, Al-Saggabi AH, Tanzi VL, Al-Badriyeh D, Alsultan HS, Ali FM, Elsisi GH, Akhras KS, Vokó Z, Kanavos P.

Expert Rev Pharmacoecon Outcomes Res. 2015;15(6):993-8. doi: 10.1586/14737167.2015.1048227. Epub 2015 Jun 18.

PMID:
26088919
14.

Baseline assessment of WHO's target for both availability and affordability of essential medicines to treat non-communicable diseases.

Ewen M, Zweekhorst M, Regeer B, Laing R.

PLoS One. 2017 Feb 7;12(2):e0171284. doi: 10.1371/journal.pone.0171284. eCollection 2017.

15.

Implication of external price referencing and parallel trade on pharmaceutical expenditure: indirect evidence from lower-income European countries.

Elek P, Takács E, Merész G, Kaló Z.

Health Policy Plan. 2017 Apr 1;32(3):349-358. doi: 10.1093/heapol/czw133.

PMID:
27697777
16.

Impact of European pharmaceutical price regulation on generic price competition: a review.

Puig-Junoy J.

Pharmacoeconomics. 2010;28(8):649-63. doi: 10.2165/11535360-000000000-00000. Review.

PMID:
20515079
17.

Payers' experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia.

Morgan SG, Vogler S, Wagner AK.

Health Policy. 2017 Apr;121(4):354-362. doi: 10.1016/j.healthpol.2017.02.002. Epub 2017 Feb 16.

18.

A pricing policy towards the sourcing of cheaper drugs in Cyprus.

Merkur S, Mossialos E.

Health Policy. 2007 May;81(2-3):368-75. Epub 2006 Sep 1.

PMID:
16949176
19.

Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?

Cameron A, Mantel-Teeuwisse AK, Leufkens HG, Laing RO.

Value Health. 2012 Jul-Aug;15(5):664-73. doi: 10.1016/j.jval.2012.04.004. Epub 2012 Jul 11.

20.

Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China.

Fang Y, Wagner AK, Yang S, Jiang M, Zhang F, Ross-Degnan D.

Lancet Glob Health. 2013 Oct;1(4):e227-37. doi: 10.1016/S2214-109X(13)70072-X. Epub 2013 Sep 24.

Supplemental Content

Support Center